SPONSOR: Sen. Hoffner DELAWARE STATE SENATE 152nd GENERAL ASSEMBLY SENATE RESOLUTION NO. 18 EXPRESSING SUPPORT FOR THE DESIGNATION OF MARCH 2024 AS NATIONAL MULTIPLE MYELOMA AWARENESS MONTH."
SPONSOR: Sen. Hoffner
SPONSOR: Sen. Hoffner
SPONSOR:
Sen. Hoffner
DELAWARE STATE SENATE
152nd GENERAL ASSEMBLY
SENATE RESOLUTION NO. 18
EXPRESSING SUPPORT FOR THE DESIGNATION OF MARCH 2024 AS NATIONAL MULTIPLE MYELOMA AWARENESS MONTH."
WHEREAS, multiple myeloma (or myeloma) is a cancer of plasma cells in the bone marrow and is called multiple because the cancer can occur at various sites in the body; and WHEREAS, multiple myeloma causes a variety of adverse health effects, including a weakened immune system, anemia, kidney damage, and bone deterioration; and WHEREAS, multiple myeloma is the second most common blood cancer worldwide; and WHEREAS, multiple myeloma currently affects more than 100,000 people in the United States, with about 35,730 new diagnoses and 12,590 deaths from the disease occurring in 2023, according to the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute; and WHEREAS, although multiple myeloma has been, and continues to be, most frequently diagnosed among those 65 and over, the disease is increasingly being diagnosed in younger individuals, including those in their 30s, 40s, and 50s; and WHEREAS, multiple myeloma is almost twice as likely to occur among African-Americans and is one of the leading causes of cancer deaths among African-Americans, with scientific understanding of the disparity remaining unknown; and WHEREAS, although the cause of multiple myeloma remains unknown, robust research is being performed in the United States and internationally into potential genetic, environmental, and other risk factors; and WHEREAS, additional new drugs and therapies are in the research phase, with patient enrollment in clinical trials playing an important role in determining safe and effective treatments; and WHEREAS, understanding and treatment of multiple myeloma has been greatly furthered by advocacy initiatives promoting awareness, education, research, peer review, and collaboration, and such efforts are to be highly commended; and WHEREAS, greater awareness of multiple myeloma among clinicians and the public can lead to earlier detection and treatment, improving health outcomes, and bringing comfort to patients and their families; and WHEREAS, March is an appropriate month to designate as National Multiple Myeloma Awareness Month. NOW, THEREFORE: BE IT RESOLVED that the Senate of the 152 nd General Assembly of the State of Delaware supports the designation of March 2024 as National Multiple Myeloma Awareness Month to increase public knowledge of the disease and advance the vision of finding a cure for multiple myeloma.
WHEREAS, multiple myeloma (or myeloma) is a cancer of plasma cells in the bone marrow and is called
multiple because the cancer can occur at various sites in the body; and
WHEREAS, multiple myeloma causes a variety of adverse health effects, including a weakened immune system,
anemia, kidney damage, and bone deterioration; and
WHEREAS, multiple myeloma is the second most common blood cancer worldwide; and
WHEREAS, multiple myeloma currently affects more than 100,000 people in the United States, with about 35,730
new diagnoses and 12,590 deaths from the disease occurring in 2023, according to the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute; and
WHEREAS, although multiple myeloma has been, and continues to be, most frequently diagnosed among those 65
and over, the disease is increasingly being diagnosed in younger individuals, including those in their 30s, 40s, and 50s; and
WHEREAS, multiple myeloma is almost twice as likely to occur among African-Americans and is one of the
leading causes of cancer deaths among African-Americans, with scientific understanding of the disparity remaining unknown; and
WHEREAS, although the cause of multiple myeloma remains unknown, robust research is being performed in the
United States and internationally into potential genetic, environmental, and other risk factors; and
WHEREAS, additional new drugs and therapies are in the research phase, with patient enrollment in clinical trials
playing an important role in determining safe and effective treatments; and
WHEREAS, understanding and treatment of multiple myeloma has been greatly furthered by advocacy initiatives
promoting awareness, education, research, peer review, and collaboration, and such efforts are to be highly commended; and
WHEREAS, greater awareness of multiple myeloma among clinicians and the public can lead to earlier detection
and treatment, improving health outcomes, and bringing comfort to patients and their families; and
WHEREAS, March is an appropriate month to designate as National Multiple Myeloma Awareness Month.
NOW, THEREFORE:
BE IT RESOLVED that the Senate of the 152 nd General Assembly of the State of Delaware supports the designation of March 2024 as National Multiple Myeloma Awareness Month to increase public knowledge of the disease and advance the vision of finding a cure for multiple myeloma.
SYNOPSIS This resolution expresses support for the designation of March 2024 as "National Multiple Myeloma Awareness Month." Author: Senator Hoffner
SYNOPSIS
This resolution expresses support for the designation of March 2024 as "National Multiple Myeloma Awareness Month."
Author: Senator Hoffner